The Tumor Test Tsunami: What Natera's Blowout Quarter Means for the MedTech Sector Natera, a biotech company with a cancer detecting blood test called Signatera, reported a remarkable second quarter performance.
Analysts praised the results, calling them "blowout" numbers. This success has sent Natera's stock soaring.
The key to this impressive performance lies in Signatera itself: a non invasive blood test that can detect microscopic pieces of tumor DNA.